17beta-HSD: Key Enzyme in The 17beta-Hydroxysteroid Cycle (P5815)

Target Name: 17-beta-Hydroxysteroid dehydrogenase

NCBI ID: P5815

Other Name(s): 17beta-HSD | 17beta-Hydroxysteroid dehydrogenase

17beta-HSD: Key Enzyme in The 17beta-Hydroxysteroid Cycle

17-beta-Hydroxysteroid dehydrogenase (17beta-HSD) is a enzyme that plays a crucial role in the synthesis of 17beta-hydroxysteroids, which are important metabolites of androgens, such as androstenedione and androsterone. 17beta-HSD is a key enzyme in the 17beta-hydroxysteroid cycle, which is a central pathway in the synthesis of androgens from androstenedione, the major metabolite of androgens.

The 17beta-hydroxysteroid cycle is a complex metabolic pathway that involves the synthesis, conversion, and catabolism of androgens. The 17beta-hydroxysteroid cycle is the first step in the synthesis of androgens from androstenedione, which is then converted to androsterone by the enzyme 17-beta-hydroxysteroid dehydrogenase (17beta-HSD).

17beta-HSD is a non-specified subunit of the 17beta-hydroxysteroid dehydrogenase enzyme, which is a key enzyme in the 17beta-hydroxysteroid cycle. The 17beta-hydroxysteroid cycle is a central pathway in the synthesis of androgens from androstenedione, which is then converted to androsterone by the enzyme 17-beta-hydroxysteroid dehydrogenase (17beta-HSD).

The 17beta-HSD enzyme is a key player in the 17beta-hydroxysteroid cycle, as it is responsible for the conversion of androstenedione to androsterone. Androstenedione is a metabolite of androgens that is produced by the 17beta-hydroxysteroid cycle. Androsterone, on the other hand, is a metabolite of androgens that is produced by the 17beta-hydroxysteroid cycle and is responsible for various physiological functions, such as maintaining bone density, regulating gene expression, and participating in the development and treatment of certain diseases.

Research has shown that 17beta-HSD is a potential drug target and biomarker for various diseases, including obesity, diabetes, and cancer. The reason for this is that changes in the levels of androgens, such as androstenedione and androsterone, have been associated with the development and progression of these diseases.

For example, obesity is associated with increased levels of androgens, such as androstenedione, which can lead to the development of various health problems, including cardiovascular disease, diabetes, and certain cancers. Similarly, diabetes is associated with decreased levels of androgens, such as androsterone, which can lead to the development of various health problems, including neuropathy, retinopathy, and certain cancers.

Cancer is also associated with changes in androgens, such as androstenedione and androsterone, which can lead to the development and progression of cancer. For example, androgens have been shown to promote the growth and progression of certain types of cancer, such as prostate cancer and breast cancer.

In addition to its role in the synthesis and catabolism of androgens, 17beta-HSD has also been shown to play a role in the regulation of gene expression. Androsterone, for example, has been shown to regulate the expression of various genes involved in the development and progression of cancer.

Furthermore, 17beta-HSD has also been shown to be involved in the regulation of bone density. Androsterone has been shown to reduce bone density and increase the risk of fractures in individuals with osteoporosis, a condition associated with decreased bone density.

In conclusion, 17beta-HSD is a non-specified subunit of the 17beta-hydroxysteroid dehydrogenase enzyme, which is a key enzyme in the 17beta-hydroxysteroid cycle. The 17beta-hydroxysteroid cycle is a central pathway in the synthesis of androgens from androstenedione, which is then converted to androsterone by

Protein Name: 17-beta-Hydroxysteroid Dehydrogenase (nonspecified Subtype)

More Common Targets